After several decades of research efforts, the treatment of AD continues to face a significant unmet need, with therapies based largely on the cholinesterase inhibitors rivastigmine, E2020, and galantamine, with the only exception an NMDA (N-methyl-d-aspartate) receptor antagonist, memantine21. This evidence concerns the gene BCHE and Alzheimer disease.